Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 31, 2024 5:27pm

104 Views

Post# 36067030

RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

ONCY's CD8+-TiLs biomarkers are determined through a minimally invasive "liquid biopsy" accomplished with a simple "blood draw" and is significantly easier to administer as a blood-based predictive diagnostic to determine biomarker levels in contrast to the present use of "tissue biopsies" that requires the invasive removal of a peice of tissue or cells to determine T cell levels, which is standard practice today.

https://jeccr.biomedcentral.com/articles/10.1186/s13046-024-02969-1

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec